Clinical trials: Psychosis
Schizophrenia
Effects of Auditory Stimulation on Sleep and Memory in Schizophrenia
The investigators will test the hypothesis that auditory stimulation (playing quiet sounds during sleep) can normalize brain activity during sleep and improve memory in patients with schizophrenia.
- Trial name
- NCT04783571
- Testing
- Auditory Stimulation
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Dental Diseases, Schizophrenia
Oral Status of Patients Suffering From SCHIZophrenia Followed at Charles Perrens Hospital
The aim of the study is to describe the oral health status of patients suffering from schizophrenia and schizoaffective disorders in a psychiatric institute in France.
- Trial name
- BUCCOSCHIZ (NCT04191200)
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
Schizophrenia
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
This trial will determine the Pharmacokinetics, safety and tolerability of single-dose Aripiprazole administered intramuscularly in adults with schizophrenia
- Trial name
- NCT03150771
- Testing
- Aripiprazole
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depression, Non-psychotic Diagnosis as Co-morbidity
The Canadian Armed Forces PEER Study
This is a prospective, single-blinded, randomized, multicenter study to evaluate the utility, safety, and efficacy of using PEER Interactive - an EEG-based technology - to inform the prescription of medications to participants…
- Trial name
- PEERCanada (NCT03625271)
- Testing
- The PEER Report
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- MYnd Analytics
Mental Disorder, General Population
Death Number Perception in Depression, Anxiety, and Schizoypal Personnality in General Population (Covid-19 Pandemic)
France has been put on a lockdown for 8 weeks to prevent the spread of the COVID-19 virus between 17/03/2020 and 11/05/2020. During this lockdown, which is likely to have psychopathological repercussions on the population, the…
- Trial name
- DeathPercep (NCT04384419)
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability.
- Trial name
- NCT02013622
- Testing
- Brexpiprazole
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia
This is a pilot study of pregnenolone as an augmentation treatment for schizophrenia. The goal of this placebo-controlled study is to provide preliminary efficacy data for potential pregnenolone effects on cognitive symptoms and…
- Trial name
- NCT00560937
- Testing
- Pregnenolone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Durham VA Medical Center
Parkinson's Disease Psychosis
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
- Trial name
- NCT00477672
- Testing
- Pimavanserin tartrate (ACP-103)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 298 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Staccato Loxapine in Agitation (Proof of Concept)
The purpose of this study is to assess efficacy and safety of Staccato Loxapine in the treatment of acute agitation in schizophrenic patients.
- Trial name
- NCT00369577
- Testing
- Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Alexza Pharmaceuticals, Inc.
Psychotic Disorder
The Effectiveness of Forest Therapy on Psychotic Patients: Focusing on Changes in Inflammatory Pathways and The Psychotic Condition of Patients
General Formulation Are there any changes in the inflammatory pathway and psychotic conditions in patients given Forest Therapy compared to conventional psychotic disorder therapy? Specific Are there any differences in the levels…
- Trial name
- FT (NCT07436481)
- Testing
- Forest Therapy
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Natalia Dewi Wardani, MD
Schizophrenia, Schizoaffective Disorder
Evaluation of mHealth for Serious Mental Illness
This study is a waitlist control trial evaluating the acceptability and preliminary efficacy of a smartphone application with people with mental illness.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT04068467
- Testing
- Smartphone App, Waitlist Control
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- University of Washington
Psychosis Prodrome
Ziprasidone in the Psychosis Prodrome
This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.
- Trial name
- ZIP (NCT00635700)
- Testing
- ziprasidone
- Where
- 11 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Yale University
Schizophrenia
Anti-Inflammatory Challenge in Schizophrenia
This study aims to illuminate the biological underpinnings of negative symptoms in schizophrenia-particularly motivational impairments-by probing the link between systemic inflammation and neural activity in reward-related brain…
- Trial name
- NCT05823532
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Schizophrenia Disorders, Major Depression
Non-Coding RNAs Gene Expression in Psychiatric Disorders
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major…
- Conditions
- Schizophrenia Disorders, Major Depression, Bipolar Affective Disorders, Obsessive Compulsive Disorder (OCD)
- Trial name
- PsiRNA26 (NCT07649993)
- Testing
- Reverse Transcription Quantitative Polymerase Chain Reaction
- Where
- 5 sites in Italy
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Carmen Concerto
Psychotic Disorders, Mood Disorders
Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations
The present study aims to examine the efficacy of transcranial direct current stimulation on the severity of auditory hallucinations.
- Conditions
- Psychotic Disorders, Mood Disorders, Personality Disorders, Stress Disorders, Post-Traumatic
- Trial name
- tDCS (NCT01977521)
- Testing
- Eldith DC Stimulator stimulation
- Where
- Netherlands
- Volunteers
- 62 people
- Sponsor
- Iris Sommer
Schizophrenia
Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
This is a study designed to evaluate the safety, tolerability, and PK of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia.
- Trial name
- SEP-363856 (NCT01994473)
- Testing
- SEP-363856, SEP-363856 Open Label
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder, Bipolar Affective Psychosis
Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.
The primary purpose of the study is to assess the efficacy of Quetiapine extended release 600mg per day either as monotherapy or combined therapy in the treatment of patients with mania associated to Bipolar disorder.
- Conditions
- Bipolar Disorder, Bipolar Affective Psychosis, Mania, Manic Disorder
- Trial name
- EMMY (NCT00521365)
- Testing
- Quetiapine 600mg
- Where
- 7 sites in Mexico
- Volunteers
- 88 people
- Sponsor
- AstraZeneca
Psychosis
A Probiotic Strategy for Antipsychotic-induced Metabolic Dysfunction
Antipsychotic drugs are used to treat a range of psychiatric disorders including schizophrenia, bipolar disorders, and psychotic depression.
- Trial name
- MetaboMicrobe (NCT06729671)
- Testing
- Bifidobacterium longum APC1472 hydroxypropylmethylcellulose (HPMC) capsule, maltodextrin
- Where
- 2 sites in Ireland
- Volunteers
- 70 people
- Sponsor
- University College Cork
Schizophrenia, Schizoaffective Disorder
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, psychotic symptoms and social functioning in schizophrenia.
- Trial name
- OTS-12WK (NCT01394471)
- Testing
- Intranasal Oxytocin Spray
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of North Carolina, Chapel Hill
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.